475 results on '"Sampson, John H"'
Search Results
2. Designing Clinical Trials for Combination Immunotherapy: A Framework for GlioblastomaCombining Immunotherapy for Glioblastoma
3. Glioblastoma Clinical Trials: Current Landscape and Opportunities for ImprovementCurrent Glioblastoma Clinical Trial Landscape
4. Utility of Routine Preoperative Urinalysis in the Prevention of Surgical Site Infections
5. Phase 2 study of bizaxofusp, an IL-4R targeted toxin payload, in nonresectable recurrent GBM: Comparison of overall survival with contemporaneous eligibility-matched and propensity score balanced external control arm.
6. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
7. IL-7 mediated upregulation of VLA-4 increases accumulation of adoptively transferred T lymphocytes in murine glioma.
8. Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma
9. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
10. Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype
11. Early Vasopressor Utilization Strategies and Outcomes in Critically Ill Patients With Severe Traumatic Brain Injury
12. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor
13. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
14. A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope
15. Utility of Routine Pre-Operative Urinalysis in the Prevention of Surgical Site Infections
16. IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA
17. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
18. Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses
19. Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy
20. Contributors
21. Brain immunology and immunotherapy in brain tumours
22. 107 ReACTOverall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma
23. ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
24. Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells
25. Immunotherapy for High-Grade Gliomas
26. Challenges to curing primary brain tumours
27. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
28. Abstract 4061: Systemic autologous lymphocyte transfer can enhance tumor-infiltrating lymphocyte infiltration in glioblastoma and license co-stimulatory immunotherapy
29. Data from Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors
30. Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
31. Supplementary Data from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
32. Supplementary Figure 7 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
33. Supplementary Figure 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
34. Supplementary Data from Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
35. Data from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
36. Table S2 from A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
37. Related Article from Regulatory T Cells Move in When Gliomas Say “I DO”
38. Supplementary Figures 1 through 4, Supplementary Table 1, and Supplementary Methods from Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors
39. Table S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
40. Supplementary Figure 5 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
41. Supplementary Figure 4 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
42. Supplementary Table 1 and 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
43. Figure Legend and Supplementary Figure 1 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
44. Supplementary Figure 3 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
45. Supplementary Figure 6 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
46. Figure S1 from A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
47. Supplementary Figure 2 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
48. Figure S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
49. Supplementary Table 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
50. Supplementary Figure 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.